华西医学

华西医学

临床药师参与低危妊娠滋养细胞肿瘤患者化学治疗的药学监护实践

查看全文

目的 通过参与低危妊娠滋养细胞肿瘤患者药物治疗实践,探讨临床药师参与肿瘤化学治疗(化疗)方案的制定和开展药学监护的方法。 方法 2015 年 1 月起临床药师参与妇科化疗病房 1 例低危妊娠滋养细胞肿瘤患者从首次化疗到疾病临床治愈的整个过程,制定化疗方案、监护临床疗效与不良反应,疗效不佳时及时更换化疗方案,积极应对患者化疗过程中的不良反应。 结果 医生采纳临床药师的建议。经过规范化的治疗,患者病情达到临床痊愈。 结论 临床药师深入临床开展药学监护,可协助医师保障患者用药更加安全有效。

Objective To explore the method of clinical pharmacists involved in the treatment of formulate the chemotherapy for cancer and pharmaceutical care, through the practice of drug treatment in patient with gestational trophoblastic neoplasia. Methods Clinical pharmacists participated in the treatment of one patient with low-risk gestational trophoblastic neoplasia in gynecological chemotherapy ward, from the first chemotherapy in January 2015 to the clinical cure. The countermeasures included designating chemotherapy regimen, monitoring clinical efficacy and adverse reactions, changing the chemotherapy redimen in time when the curative effect was poor, and coping with adverse reactions. Results Physicians adopted the suggestions from clinical pharmacists and the patient was clinically cured after standardized treatment. Conclusion Pharmaceutical care by clinical pharmacists can assist clinicians to ensure the safety and effectiveness of drug use.

关键词: 临床药师; 妊娠滋养细胞肿瘤; 药学监护; 工作实践

Key words: Clinical pharmacist; Gestational trophoblastic neoplasia; Pharmaceutical care; Work practice

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. 沈铿, 崔恒, 丰有吉. 常见妇科恶性肿瘤诊治指南. 4 版. 北京: 人民卫生出版社, 2014: 115-135.
2. Morgan JM, Lurain JR. Gestatinal trophoblastic neoplasia: an update. Curr Oncol Rep, 2008, 10(6): 497-504.
3. Smith HO, Wiggins C, Verschraegen CF, et al. Changing trends in gestational trophoblastic disease. J Reprod Med, 2006, 51(10): 777-784.
4. Cole LA, Butler SA, Khanlian SA, et al. Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia. Gynecol Oncol, 2006, 102(2): 151-159.
5. 朱晓旭, 钱建华, 掌佩文, 等. 不同 HCG 水平妊娠滋养细胞肿瘤的临床特征和治疗分析. 浙江医学, 2016, 38(9): 611-613.
6. Lertkhachonsuk AA, Israngura N, Wilailak S, et al. Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial. Int J Gynecol Cancer, 2009, 19(5): 985-988.
7. Deng LY, Zhang J, Wu TX, et al. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev, 2013(1): CD005196.
8. Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. Gynecol Oncol, 2005, 97(2): 618-623.
9. Yarandi F, Eftekhar Z, Shojaei H, et al. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Int J Gynaecol Obstet, 2008, 103(1): 33-37.
10. Osborne RJ, Filiaci V, Schink JC, et al. Phase Ⅲ trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol, 2011, 29(7): 825-831.
11. Gilani MM, Yarandi F, Eftekhar Z, et al. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust N Z J Obstet Gynaecol, 2005, 45(2): 161-164.
12. Alazzam M, Tidy J, Hancock BW, et al. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev, 2012(7): CD007102.
13. Osborne R, Gerulath A. What is the best regimen for low-risk gestational trophoblastic neoplasia. A review. J Reprod Med, 2004, 49(8): 602-616.
14. Mcneish IA, Strickland S, Holden L, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol, 2002, 20(7): 1838-1844.
15. 刘建军, 崔林, 张志胜. 重组人粒细胞集落刺激因子对化疗后粒细胞下降的疗效观察. 肿瘤研究与临床, 2006, 18(12): 848-849.